Since the success of imatinib in the treatment of chronic myeloid leukemia, tyrosine kinase inhibitors have been shown to be both efficacious and well tolerated despite absolute specificity for a single kinase. Consequently, multiple tyrosine kinase inhibitors have been approved and many more are in development. The JAK family of tyrosine kinases consists of 4 cytoplasmic proteins, which are obligatorily required for Type I/II cytokine receptors to signal and activate intracellular signaling pathways. They are critical for the function of over 60 cytokines and are therefore attractive targets for the generation of new immunomodulatory and oncology drugs.
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